Breast Cancer, Peking University People's Hospital
Breast Cancer, Peking University People's Hospital
Beijing, Beijing Municipality, China1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study | Germline BRCA-mutated HER2-negative Breast Cancer | Recruiting | Phase 2 | 2026-07-21 | NCT05576389 |